TLDR: ValGenesis, a leader in digital validation lifecycle management, has successfully secured $16 million in funding from the Innovation Banking Group at Bridge Bank. This significant investment is earmarked for the global expansion of its AI-enabled validation solutions, strategic hiring, and enhancing customer success across North America, Europe, and Asia-Pacific.
Santa Clara, CA – ValGenesis, a pioneering company specializing in digital validation lifecycle management, announced today it has secured $16 million in new funding. The investment was provided by the Innovation Banking Group at Bridge Bank, signaling strong confidence in ValGenesis’s vision and technological advancements.
The capital infusion is strategically allocated to fuel ValGenesis’s ambitious global expansion plans, particularly focusing on its cutting-edge AI-enabled validation solutions. The funds will support strategic hiring initiatives, facilitate regional partner expansion across key markets including North America, Europe, and Asia-Pacific, and bolster customer success programs.
Under the leadership of CEO Dr. Siva Samy, ValGenesis is dedicated to empowering global organizations to enhance product quality and accelerate the delivery of consistent, safer products. The company achieves this through its integrated, cloud-based, AI-enabled platform designed for end-to-end product lifecycle digitalization. This platform unifies intelligent, risk-based validation with process automation within a connected ecosystem, thereby streamlining operations, ensuring compliance, and mitigating risks.
A cornerstone of ValGenesis’s offering is ValGenesis Smart GxP, an AI-enabled platform recently launched and purpose-built to unify validation and process lifecycle management across life sciences organizations. This innovative solution is widely adopted by pharmaceutical, biotech, and medical device organizations to digitize and automate their validation lifecycle processes, ensuring compliance, traceability, and efficiency at scale.
Also Read:
- Xelix Secures $160 Million Series B to Propel Agentic AI in Accounts Payable
- Metly Raises €520K Pre-Seed to Revolutionize Pharma Business Development with AI
This investment underscores ValGenesis’s commitment to advancing digital transformation in regulated industries, leveraging artificial intelligence to bring greater efficiency and reliability to critical validation processes worldwide.
